Abstract
In recent years, target therapies to specific molecular alterations present in non-small cell lung cancer (NSCLC) patients have been discovered and have shown superior efficacy compared to non-targeted treatments. Among the molecular alterations identified in NSCLC, the anaplastic lymphoma tyrosine kinase (ALK) receptor, present in 3.4% of patients, is one of the therapeutic targets. The aim of this study was to estimate in monetary terms the value of the benefit of ALK diagnosis in NSCLC in Spain.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
